-

$undefined

N/A

(N/A)

Biomea Fusion NASDAQ:BMEA Biomea Fusion, Inc. operates as a biopharmaceutical company. The Company focuseS on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Biomea Fusion serves customers in the United States.

Location: | Website: www.biomeafusion.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services

Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

13.3M

Cash

87.95M

Avg Qtr Burn

-28.18M

Short % of Float

39.54%

Insider Ownership

25.02%

Institutional Own.

63.55%

Qtr Updated

09/30/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
BMF-219 (icovamenib) Details Type 2 diabetes	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BMF-219 (icovamenib) Details Type 1 diabetes Big Mover™ Suspected Mover™ Susp. Mover™	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BMF-219 (icovamenib) + GLP-1-based therapy Details Obesity	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BMF-219 (icovamenib) Details Solid tumor/s, Colorectal cancer , Pancreatic cancer, Non-small cell lung carcinoma	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BMF-219 (icovamenib) Details Acute myeloid leukemia, Acute lymphoblastic leukemia	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
BMF-500 Details Leukemia	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.